Division of Endocrinology, Metabolism and Diabetes, and Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA.
J Clin Endocrinol Metab. 2011 Jun;96(6):1654-63. doi: 10.1210/jc.2011-0585.
This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care.
An international working group of 32 experts in the pathophysiology, genetics, clinical trials, and clinical care of obesity and/or type 2 diabetes participated in a conference held on 6-7 January 2011 and cosponsored by The Endocrine Society, the American Diabetes Association, and the European Association for the Study of Diabetes. A writing group comprising eight participants subsequently prepared this summary and recommendations. Participants reviewed and discussed published literature and their own unpublished data.
The writing group unanimously supported the summary and recommendations as representing the working group's majority or unanimous opinions.
The major questions linking obesity to type 2 diabetes that need to be addressed by combined basic, clinical, and population-based scientific approaches include the following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what mechanisms do obesity and insulin resistance contribute to β-cell decompensation, and if/when obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3) How does the duration of type 2 diabetes relate to the benefits of weight reduction by lifestyle, weight-loss drugs, and/or bariatric surgery on β-cell function and glycemia? 4) What is necessary for regulatory approval of medications and possibly surgical approaches for preventing type 2 diabetes in patients with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance effective and cost-effective interventions for both conditions, including more tailored therapy. To expedite this process, we recommend further investigation into the pathogenesis of these coexistent conditions and innovative approaches to their pharmacological and surgical management.
本报告探讨了肥胖症与 2 型糖尿病之间的关系,并就如何在这些领域开展未来的研究以促进预防、干预和整体患者护理提出了建议。
一个由 32 名肥胖症和/或 2 型糖尿病病理生理学、遗传学、临床试验和临床护理领域的国际专家组成的工作组参加了 2011 年 1 月 6 日至 7 日举行的会议,会议由内分泌学会、美国糖尿病协会和欧洲糖尿病研究协会共同主办。一个由 8 名成员组成的写作小组随后编写了这份总结和建议。参与者查阅并讨论了已发表的文献和他们自己未发表的数据。
写作小组成员一致支持该总结和建议,认为它们代表了工作组的多数或一致意见。
需要通过综合的基础、临床和基于人群的科学方法来解决与肥胖症相关的 2 型糖尿病的主要问题,包括以下几点:1)为什么并非所有肥胖症患者都会发展为 2 型糖尿病?2)肥胖症和胰岛素抵抗通过何种机制导致β细胞功能失代偿,如果/当肥胖症可以预防时,将会有多少 2 型糖尿病的发病率降低?3)2 型糖尿病的病程与生活方式、减肥药物和/或减肥手术对β细胞功能和血糖的减肥效果之间存在何种关系?4)在肥胖症患者中预防 2 型糖尿病的药物和可能的手术方法需要哪些监管部门的批准?更好地了解肥胖症与 2 型糖尿病之间的关系可能有助于推进针对这两种疾病的有效和具有成本效益的干预措施,包括更具针对性的治疗。为了加快这一进程,我们建议进一步研究这些共存疾病的发病机制,并探索其药理学和手术管理的创新方法。